Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.

Cohn DE, Kim KH, Resnick KE, O'Malley DM, Straughn JM Jr.

J Clin Oncol. 2011 Apr 1;29(10):1247-51. doi: 10.1200/JCO.2010.32.1075. Epub 2011 Mar 7.

2.

A cost-utility analysis of NRG Oncology/Gynecologic Oncology Group Protocol 218: incorporating prospectively collected quality-of-life scores in an economic model of treatment of ovarian cancer.

Cohn DE, Barnett JC, Wenzel L, Monk BJ, Burger RA, Straughn JM Jr, Myers ER, Havrilesky LJ.

Gynecol Oncol. 2015 Feb;136(2):293-9. doi: 10.1016/j.ygyno.2014.10.020. Epub 2014 Oct 23.

3.

Big costs for little gain in ovarian cancer.

Hensley ML.

J Clin Oncol. 2011 Apr 1;29(10):1230-2. doi: 10.1200/JCO.2010.34.0489. Epub 2011 Mar 7. No abstract available.

4.

Consolidation paclitaxel is more cost-effective than bevacizumab following upfront treatment of advanced epithelial ovarian cancer.

Lesnock JL, Farris C, Krivak TC, Smith KJ, Markman M.

Gynecol Oncol. 2011 Sep;122(3):473-8. doi: 10.1016/j.ygyno.2011.05.014. Epub 2011 Jun 12.

5.

Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer.

Mehta DA, Hay JW.

Gynecol Oncol. 2014 Mar;132(3):677-83. doi: 10.1016/j.ygyno.2014.01.021. Epub 2014 Jan 23.

PMID:
24463160
6.

Management of platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.

Havrilesky LJ, Secord AA, Kulasingam S, Myers E.

Gynecol Oncol. 2007 Nov;107(2):211-8. Epub 2007 Sep 17.

PMID:
17870150
7.

Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer.

Havrilesky LJ, Pokrzywinski R, Revicki D, Higgins RV, Nycum LR, Kohler MF, Berchuck A, Myers ER, Secord AA.

Cancer. 2012 Jan 15;118(2):386-91. doi: 10.1002/cncr.26199. Epub 2011 May 19.

8.

Bevacizumab in treatment of high-risk ovarian cancer--a cost-effectiveness analysis.

Chan JK, Herzog TJ, Hu L, Monk BJ, Kiet T, Blansit K, Kapp DS, Yu X.

Oncologist. 2014 May;19(5):523-7. doi: 10.1634/theoncologist.2013-0322. Epub 2014 Apr 10.

9.

An economic analysis of dose dense weekly paclitaxel plus carboplatin versus every-3-week paclitaxel plus carboplatin in the treatment of advanced ovarian cancer.

Dalton HJ, Yu X, Hu L, Kapp DS, Benjamin I, Monk BJ, Chan JK.

Gynecol Oncol. 2012 Feb;124(2):199-204. doi: 10.1016/j.ygyno.2011.09.028. Epub 2011 Nov 4.

PMID:
22055763
10.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

11.

PARP inhibitor maintenance therapy for patients with platinum-sensitive recurrent ovarian cancer: a cost-effectiveness analysis.

Smith HJ, Walters Haygood CL, Arend RC, Leath CA 3rd, Straughn JM Jr.

Gynecol Oncol. 2015 Oct;139(1):59-62. doi: 10.1016/j.ygyno.2015.08.013. Epub 2015 Aug 22.

PMID:
26303225
12.

A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.

Montero AJ, Avancha K, Gl├╝ck S, Lopes G.

Breast Cancer Res Treat. 2012 Apr;132(2):747-51. doi: 10.1007/s10549-011-1919-y. Epub 2011 Dec 27.

PMID:
22200867
13.
14.

Cost effectiveness of alternative strategies for incorporating bevacizumab into the primary treatment of ovarian cancer.

Barnett JC, Alvarez Secord A, Cohn DE, Leath CA 3rd, Myers ER, Havrilesky LJ.

Cancer. 2013 Oct 15;119(20):3653-61. doi: 10.1002/cncr.28283. Epub 2013 Aug 6.

15.

Intraperitoneal cisplatin and paclitaxel versus intravenous carboplatin and paclitaxel chemotherapy for Stage III ovarian cancer: a cost-effectiveness analysis.

Bristow RE, Santillan A, Salani R, Diaz-Montes TP, Giuntoli RL 2nd, Meisner BC, Armstrong DK, Frick KD.

Gynecol Oncol. 2007 Sep;106(3):476-81. Epub 2007 Aug 3.

PMID:
17688927
16.

Cost effectiveness of intraperitoneal compared with intravenous chemotherapy for women with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Havrilesky LJ, Secord AA, Darcy KM, Armstrong DK, Kulasingam S; Gynecologic Oncology Group.

J Clin Oncol. 2008 Sep 1;26(25):4144-50. doi: 10.1200/JCO.2007.13.1961.

17.
18.
19.

Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.

Young M, Plosker GL.

Pharmacoeconomics. 2001;19(12):1227-59. Review.

PMID:
11772158
20.

NICE guidance on bevacizumab in combination with paclitaxel and carboplatin for the first-line treatment of advanced ovarian cancer.

Dyer M, Richardson J, Robertson J, Adam J.

Lancet Oncol. 2013 Jul;14(8):689-90. doi: 10.1016/S1470-2045(13)70248-1. Epub 2013 May 22. No abstract available.

PMID:
23706983
Items per page

Supplemental Content

Write to the Help Desk